Screener
Summit Therapeutics SMMT Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by Summit Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:EmployeeRelatedLiabilitiesCurrent.
The source filing: Summit Therapeutics’s 10-Q, filed April 30, 2026.
- Filed
- Apr 30, 2026, 5:00 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001599298-26-000039
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Current liabilities: | ||
| Accounts payable | $27,549 | $20,292 |
| Accrued liabilities | 44,317 | 32,100 |
| Accrued compensation | 7,073 | 14,925 |
| Operating lease liabilities, current portion | 3,179 | 3,388 |
| Other current liabilities | 1,148 | 2,283 |
| Total current liabilities | 83,266 | 72,988 |
| Non-current liabilities: |
Item 1. Financial Statements.
FAQ
- What is Summit Therapeutics's accrued expenses?
- Summit Therapeutics (SMMT) reported accrued expenses of $7.07M in Q1 2026.
- How has Summit Therapeutics's accrued expenses changed year-over-year?
- Summit Therapeutics's accrued expenses increased by 60.9% year-over-year, from $4.4M to $7.07M.
- What is the long-term trend for Summit Therapeutics's accrued expenses?
- Over 5 years (2020 to 2025), Summit Therapeutics's accrued expenses has grown at a 72.3% compound annual growth rate (CAGR), from $983K to $14.93M.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.
Ask your AI about Summit Therapeutics's accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude